当前位置:首页>产品中心>单抗/多抗>Anti-Human OX40 Ligand/TNFSF4 Reference Antibody|抗人OX40配体/TNFSF4参考抗体(靶标:人OX40配体)

Anti-Human OX40 Ligand/TNFSF4 Reference Antibody|抗人OX40配体/TNFSF4参考抗体(靶标:人OX40配体)

  • 货号:RB9THW342196
  • 价格:面议
  • 点击:260

产品介绍

产品参数

形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型IgG1-kappa
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号P43489
背景信息Ivuxolimab (PF-04518600) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response
• Targeting co-stimulatory molecules in autoimmune disease., PMID:32939077
• OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520
• The role of OX40 ligand/OX40 axis signalling in atopic dermatitis., PMID:38836560
• Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists., PMID:39636970
• An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026
• Entry of betaherpesviruses., PMID:31439151
• OX40 (CD134) and OX40L., PMID:19760068
• Research progress in OX40/OX40L in allergic diseases., PMID:39404736
• The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity., PMID:37932534
• The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia., PMID:34453673
别名2768487-95-0
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 408
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 520
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 351
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 486
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 359
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 449
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 216
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 279
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 230
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 437
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 547
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 355
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 347
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 531
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 565
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 383
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 230
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 555
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 437
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 235
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00